Cerecor Inc. Company Review & Valuation
About Cerecor Inc.
Cerecor Inc., a pharmaceutical company, focuses on pediatric health care.
Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.
It also offers Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension; and Flexichamber.
The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and two preclinical stage development candidates, CERC-406 and CERC-425 potential for the treatment of motoric and non-motoric symptoms of Parkinson's disease, as well as other psychiatric and neurological conditions.
The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc.
in March 2011.
was founded in 2011 and is headquartered in Baltimore, Maryland.